(NewsDirect)
Willow Bioscience CEO Dr Chris Savilejoined Steve Darling from Proactive to share news the company hasembarked on a major strategic shift, focusing its commercial effortson the BioOxi platform. To assist in this transition, WillowBiosciences has engaged an advisor to explore and evaluate potentialopportunities.
This move is part ofa broader strategy that also encompasses a collaborative venture witha Nasdaq-listed biopharmaceutical company. Together, they are workingto establish sustainable manufacturing routes for key intermediatesand active pharmaceutical ingredients.
Savile highlighted the company's achievements in executingsuccessful commercial programs. Notably, four new programs linked tothe BioOxi bio-oxidation platform technology were launched in April2023.
Willow Biosciences is nowconcentrating on partner-funded enzyme engineering engagements, astrategic shift aimed at enhancing cost efficiency and optimizing thepathway to revenue growth.
Thisrefocusing strategy aligns with the company's commitment tounlocking nearer-term and potentially larger revenue opportunities,particularly compared to its legacy strain engineering business.
Furthermore, Savile shared insights intothe company's operational evolution. Willow Biosciences hascompleted a seamless transition, consolidating its operations into asingle, cost-efficient facility located in Sunnyvale, California. Thisfacility not only caters to the present needs of the company but alsoaccommodates future growth prospects.
With ample laboratoryspace, Willow Biosciences can continue to expand its collaborativeefforts while maintaining a financially prudent approach, in contrastto previous locations. bolstered by cost-effective operations and afocused commercial approach.
ContactDetails
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.